Approximately 30% of newly diagnosed patients with acute myeloid leukemia (AML) harbor mutations in FMS-like tyrosine kinase receptor 3 (FLT3), which confer a poor disease prognosis (recently reviewed by Daver et al., 2019 ▸). This evidence concerns the gene FLT3 and acute myeloid leukemia.